{
    "id": "dbpedia_1851_2",
    "rank": 57,
    "data": {
        "url": "https://synapse.patsnap.com/drug/d8dedb763e17488b861672c2644d4b3e",
        "read_more_link": "",
        "language": "en",
        "title": "Drug Targets, Indications, Patents",
        "top_image": "https://synapse-static.patsnap.com/static/synapse-logo-us.png",
        "meta_img": "https://synapse-static.patsnap.com/static/synapse-logo-us.png",
        "images": [
            "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/11ef/8a9e/8bf5/ca80/213a/1183/511c/ded3/577289a9efbc495d_48w.webp",
            "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/0844/2d3f/137c/c088/f729/9c64/2e14/31f1/3e290df864401e33_48w.webp",
            "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/ce17/8347/1a7a/dd83/7e10/62d8/5249/c974/75dbc5cdcd8ae641_48w.webp",
            "https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/sequence.6e52690d.png",
            "https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/sequence.6e52690d.png",
            "https://images.crunchbase.com/image/upload/t_cb-default-original/piqz9qqu4rn51556vf7m",
            "https://images.crunchbase.com/image/upload/t_cb-default-original/piqz9qqu4rn51556vf7m",
            "https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/en-translational-medicine.3a3e2795.png",
            "https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/en-drug-deal.a0b20458.png",
            "https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/en-core-patent.b641c7b0.png",
            "https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/en-clinical-trial.0b31c1c7.png",
            "https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/en-approval.afa46671.png",
            "https://synapse-static.patsnap.com/ssr/ac0dc40f/_nuxt/en-regulation.1032cd3e.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "VGL-101",
            "Iluzanebart",
            "TREM2 stimulants",
            "Hereditary Diffuse Leukoencephalopathy With Spheroids"
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "VGL-101: a TREM2 stimulants Drug, Initially developed by Amgen, Inc., Now, its global highest R&D status is Phase 2, Mechanism: TREM2 stimulants(Triggering receptor expressed on myeloid cells 2 stimulants), Therapeutic Areas: Nervous System Diseases,Congenital Disorders,Endocrinology and Metabolic Disease, Active Indication: Hereditary Diffuse Leukoencephalopathy With Spheroids,Alzheimer Disease,Hair Defect With Photosensitivity and Mental Retardation, Active Org.: Vigil Neuroscience, Inc.,Mayo Clinic,Medical Consultant Accounts Ltd..",
        "meta_lang": "en",
        "meta_favicon": "/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://synapse.patsnap.com/drug/d8dedb763e17488b861672c2644d4b3e",
        "text": "Corporate Publications\n\nManual\n\nPhase 1\n\n82\n\nypxiaqilst(stumbjipew) = No reports of Serious Adverse Events cevuvlldfy (bgwplbdecm )\n\nView more\n\nPositive"
    }
}